JP7329503B2 - 重篤患者用の療法モニタリングマーカーとしてのｐｒｏ－ａｄｍ - Google Patents

重篤患者用の療法モニタリングマーカーとしてのｐｒｏ－ａｄｍ Download PDF

Info

Publication number
JP7329503B2
JP7329503B2 JP2020515677A JP2020515677A JP7329503B2 JP 7329503 B2 JP7329503 B2 JP 7329503B2 JP 2020515677 A JP2020515677 A JP 2020515677A JP 2020515677 A JP2020515677 A JP 2020515677A JP 7329503 B2 JP7329503 B2 JP 7329503B2
Authority
JP
Japan
Prior art keywords
proadm
fragments
sample
level
patient
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
JP2020515677A
Other languages
English (en)
Japanese (ja)
Other versions
JP2020533604A5 (https=
JP2020533604A (ja
Inventor
ダライアス ウィルソン
Original Assignee
ベー．エル．アー．ハー．エム．エス ゲゼルシャフト ミット ベシュレンクテル ハフツング
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by ベー．エル．アー．ハー．エム．エス ゲゼルシャフト ミット ベシュレンクテル ハフツング filed Critical ベー．エル．アー．ハー．エム．エス ゲゼルシャフト ミット ベシュレンクテル ハフツング
Publication of JP2020533604A publication Critical patent/JP2020533604A/ja
Publication of JP2020533604A5 publication Critical patent/JP2020533604A5/ja
Priority to JP2023006500A priority Critical patent/JP7544879B2/ja
Application granted granted Critical
Publication of JP7329503B2 publication Critical patent/JP7329503B2/ja
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/68—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids
    • G01N33/6893—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids related to diseases not provided for elsewhere
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K49/00—Preparations for testing in vivo
    • A61K49/0004—Screening or testing of compounds for diagnosis of disorders, assessment of conditions, e.g. renal clearance, gastric emptying, testing for diabetes, allergy, rheuma, pancreas functions
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/74—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving hormones or other non-cytokine intercellular protein regulatory factors such as growth factors, including receptors to hormones and growth factors
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2333/00—Assays involving biological materials from specific organisms or of a specific nature
    • G01N2333/435—Assays involving biological materials from specific organisms or of a specific nature from animals; from humans
    • G01N2333/575—Hormones
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2800/00—Detection or diagnosis of diseases
    • G01N2800/22—Haematology
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2800/00—Detection or diagnosis of diseases
    • G01N2800/26—Infectious diseases, e.g. generalised sepsis
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2800/00—Detection or diagnosis of diseases
    • G01N2800/52—Predicting or monitoring the response to treatment, e.g. for selection of therapy based on assay results in personalised medicine; Prognosis
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2800/00—Detection or diagnosis of diseases
    • G01N2800/56—Staging of a disease; Further complications associated with the disease

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Molecular Biology (AREA)
  • Urology & Nephrology (AREA)
  • Biomedical Technology (AREA)
  • Hematology (AREA)
  • Immunology (AREA)
  • Chemical & Material Sciences (AREA)
  • Pathology (AREA)
  • General Health & Medical Sciences (AREA)
  • Analytical Chemistry (AREA)
  • Microbiology (AREA)
  • Food Science & Technology (AREA)
  • Medicinal Chemistry (AREA)
  • Physics & Mathematics (AREA)
  • Cell Biology (AREA)
  • Biochemistry (AREA)
  • Biotechnology (AREA)
  • General Physics & Mathematics (AREA)
  • Endocrinology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Diabetes (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Rheumatology (AREA)
  • Toxicology (AREA)
  • Epidemiology (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Investigating Or Analysing Biological Materials (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Peptides Or Proteins (AREA)
JP2020515677A 2017-09-13 2018-09-13 重篤患者用の療法モニタリングマーカーとしてのｐｒｏ－ａｄｍ Active JP7329503B2 (ja)

Priority Applications (1)

Application Number Priority Date Filing Date Title
JP2023006500A JP7544879B2 (ja) 2017-09-13 2023-01-19 重篤患者用の療法モニタリングマーカーとしてのｐｒｏ－ａｄｍ

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
EP17190912.0 2017-09-13
EP17190912 2017-09-13
PCT/EP2018/074722 WO2019053115A1 (en) 2017-09-13 2018-09-13 USE OF PROADM AS A THERAPEUTIC SURVEILLANCE MARKER FOR CRITICALLY PHASE PATIENTS

Related Child Applications (1)

Application Number Title Priority Date Filing Date
JP2023006500A Division JP7544879B2 (ja) 2017-09-13 2023-01-19 重篤患者用の療法モニタリングマーカーとしてのｐｒｏ－ａｄｍ

Publications (3)

Publication Number Publication Date
JP2020533604A JP2020533604A (ja) 2020-11-19
JP2020533604A5 JP2020533604A5 (https=) 2021-03-25
JP7329503B2 true JP7329503B2 (ja) 2023-08-18

Family

ID=59887050

Family Applications (4)

Application Number Title Priority Date Filing Date
JP2020515677A Active JP7329503B2 (ja) 2017-09-13 2018-09-13 重篤患者用の療法モニタリングマーカーとしてのｐｒｏ－ａｄｍ
JP2020515760A Active JP7366007B2 (ja) 2017-09-13 2018-09-13 プロアドレノメジュリンに基づく輸液療法のガイダンスのための方法
JP2023006500A Active JP7544879B2 (ja) 2017-09-13 2023-01-19 重篤患者用の療法モニタリングマーカーとしてのｐｒｏ－ａｄｍ
JP2023175415A Abandoned JP2023181226A (ja) 2017-09-13 2023-10-10 プロアドレノメジュリンに基づく輸液療法のガイダンスのための方法

Family Applications After (3)

Application Number Title Priority Date Filing Date
JP2020515760A Active JP7366007B2 (ja) 2017-09-13 2018-09-13 プロアドレノメジュリンに基づく輸液療法のガイダンスのための方法
JP2023006500A Active JP7544879B2 (ja) 2017-09-13 2023-01-19 重篤患者用の療法モニタリングマーカーとしてのｐｒｏ－ａｄｍ
JP2023175415A Abandoned JP2023181226A (ja) 2017-09-13 2023-10-10 プロアドレノメジュリンに基づく輸液療法のガイダンスのための方法

Country Status (7)

Country Link
US (3) US20200300864A1 (https=)
EP (2) EP3682245A1 (https=)
JP (4) JP7329503B2 (https=)
CN (2) CN111065927B (https=)
BR (1) BR112020004138A2 (https=)
CA (1) CA3075440A1 (https=)
WO (2) WO2019053116A1 (https=)

Families Citing this family (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2026013199A1 (en) 2024-07-12 2026-01-15 Cezanne S.A.S. Clinical immunoassay with early signal measurement
CN118976116B (zh) * 2024-10-22 2025-01-24 四川大学华西医院 琥珀酰明胶在制备腹膜透析液中的用途以及一种含琥珀酰明胶、枸橼酸钠的腹膜透析液

Citations (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2008012019A2 (de) 2006-07-24 2008-01-31 B.R.A.H.M.S. Aktiengesellschaft Verfahren zur steuerung der therapie von patienten mit herzinsuffizienz anhand der in vitro bestimmung von schwellenwerten von vasoaktiven peptiden
US20080213746A1 (en) 2006-11-09 2008-09-04 Leong Loke Ng Methods of Diagnosis and Risk Stratification of Adverse Events in Post Myocardial Infarction Patients Using Pro-adrenomedullin
JP2012526271A (ja) 2009-05-05 2012-10-25 ベー．エル．アー．ハー．エム．エス ゲゼルシャフト ミット ベシュレンクテル ハフツング 内皮性機能／機能不全に関連した疾患に罹患している患者の血管作動性ホルモンに基づいた層化
JP2013541015A (ja) 2010-11-01 2013-11-07 ベー．エル．アー．ハー．エム．エス ゲゼルシャフト ミット ベシュレンクテル ハフツング 非特異的症状を有する患者の予後及びリスク評価
JP2016521315A (ja) 2013-04-19 2016-07-21 ユナイテッド テクノロジーズ コーポレイションＵｎｉｔｅｄ Ｔｅｃｈｎｏｌｏｇｉｅｓ Ｃｏｒｐｏｒａｔｉｏｎ 付加製造のためのビルドプレート及び装置

Family Cites Families (28)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
FR2570703B1 (fr) 1984-09-26 1988-07-08 Commissariat Energie Atomique Complexes macropolycycliques de terres rares et application a titre de marqueurs fluorescents
US4882733A (en) 1987-03-13 1989-11-21 Ford Aerospace Corporation Method and apparatus for combining encoding and modulation
FR2664699B1 (fr) 1990-07-13 1995-08-18 Cis Bio Int Procede d'amplification du signal d'emission d'un compose luminescent.
DE69602756T2 (de) 1995-08-18 2000-02-10 The Government Of The United States Of America As Represented By The Secretary Of The Department Of Health And Human Services, Rockville Funktionelle rolle von adrenomedullin(am) und dem gen-verwandten produkt(pamp) in der menschlichen pathologie und physiologie
KR100425525B1 (ko) 2000-11-21 2004-03-30 재단법인서울대학교산학협력재단 조산과 태아감염 및 태아손상을 산전 진단하기 위한진단시약 및 진단키트
US6864237B2 (en) * 2002-05-17 2005-03-08 Ping Wang Treatment of shock using adrenomedullin and adrenomedullin binding protein-1
DE10316583A1 (de) 2003-04-10 2004-10-28 B.R.A.H.M.S Aktiengesellschaft Bestimmung eines midregionalen Proadrenomedullin-Teilpeptids in biologischen Flüssigkeiten zu diagnostischen Zwecken, sowie Immunoassays für die Durchführung einer solchen Bestimmung
CN101208602A (zh) * 2005-04-15 2008-06-25 贝克顿迪金森公司 脓毒症的诊断
DE102006060112A1 (de) 2006-12-20 2008-06-26 Brahms Aktiengesellschaft Diagnose und Risikostratifizierung mittels dem neuen Marker CT-proADM
US8298774B2 (en) 2007-03-12 2012-10-30 Biomedica Medizinprodukte Gmbh & Co Kg Diagnosis of septic complications
PL2185937T5 (pl) 2007-09-07 2014-12-31 Univ Zuerich Sposób wykrywania posocznicy u ludzi
ES2486268T3 (es) 2007-11-16 2014-08-18 Biocartis Nv Biomarcadores y procedimientos de diagnóstico, predicción y/o pronóstico de septicemia y usos de los mismos
JP5989965B2 (ja) * 2008-01-08 2016-09-07 メルク シャープ エンド ドーム リミテッド ２−｛４−［（３ｓ）−ピペリジン−３−イル］フェニル｝−２ｈ−インダゾール−７−カルボキサミドの薬学的に許容される塩
EP2131200A1 (en) * 2008-06-04 2009-12-09 BRAHMS Aktiengesellschaft A marker for graft failure and mortality
JP5702371B2 (ja) * 2009-05-27 2015-04-15 デイナ ファーバー キャンサー インスティチュート，インコーポレイテッド Ｍｕｃ１のアンタゴニストを使用した、炎症の阻害
EP2438447B1 (en) 2009-06-05 2015-02-18 B.R.A.H.M.S GmbH Detection of bacterial infections in subjects suffering from dyspnea.
US8383332B2 (en) 2009-10-13 2013-02-26 B.R.A.H.M.S. Gmbh Procalcitonin for the diagnosis of bacterial infections and guidance of antibiotic treatment in patients with acute stroke or transient ischemic attack
EP2545379B1 (en) 2010-03-08 2015-09-30 B.R.A.H.M.S GmbH Procalcitonin for the diagnosis of bacterial infections and guidance of antibiotic treatment in patients with non-specific complaints
SG11201402362VA (en) * 2011-11-16 2014-06-27 Adrenomed Ag Anti-adrenomedullin (adm) antibody or anti-adm antibody fragment or anti-adm non-ig scaffold for reducing the risk of mortality in a patient having a chronic or acute disease or acute condition
CA2856150A1 (en) * 2011-11-16 2013-05-23 Adrenomed Ag Anti-adrenomedullin (adm) antibody or anti-adm antibody fragment or anti-adm non-ig scaffold for regulating the fluid balance in a patient having a chronic or acute disease
US11067586B2 (en) * 2011-11-16 2021-07-20 Sphingotec Gmbh Adrenomedullin assays and methods for determining mature adrenomedullin
DK2780717T3 (en) * 2011-11-16 2017-02-13 Sphingotec Gmbh ADRENOMEDULLINASSAYS AND METHODS FOR DETERMINING MODERN ADRENOMEDULLIN
US10935548B2 (en) 2011-12-08 2021-03-02 Astute Medical, Inc. Methods for diagnosis and prognosis of renal injury and renal failure using insulin-like growth factor-binding protein 7 and metalloproteinase inhibitor 2
EP2637023A1 (en) * 2012-03-08 2013-09-11 B.R.A.H.M.S GmbH Prediction of outcome in patients with chronic obstructive pulmonary disease
EP2976646B1 (en) * 2013-03-20 2020-08-19 sphingotec GmbH Adrenomedullin to guide therapy of blood pressure decline
US20180348235A1 (en) 2015-11-27 2018-12-06 B.R.A.H.M.S Gmbh MR-proADM as marker for the extracellular volume status of a subject
EP4231018A3 (en) 2016-07-08 2023-11-15 SphingoTec GmbH Adrenomedullin for assessing congestion in a subject with acute heart failure
CA3033094A1 (en) 2016-08-09 2018-02-15 B.R.A.H.M.S Gmbh Histones and/or proadm as markers indicating an adverse event

Patent Citations (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2008012019A2 (de) 2006-07-24 2008-01-31 B.R.A.H.M.S. Aktiengesellschaft Verfahren zur steuerung der therapie von patienten mit herzinsuffizienz anhand der in vitro bestimmung von schwellenwerten von vasoaktiven peptiden
JP2009544951A (ja) 2006-07-24 2009-12-17 ベー・エル・アー・ハー・エム・エス・アクティエンゲゼルシャフト 血管作動性ペプチドの閾値をインビトロで測定することによって心機能不全を患う患者の治療を管理する方法
US20080213746A1 (en) 2006-11-09 2008-09-04 Leong Loke Ng Methods of Diagnosis and Risk Stratification of Adverse Events in Post Myocardial Infarction Patients Using Pro-adrenomedullin
JP2012526271A (ja) 2009-05-05 2012-10-25 ベー．エル．アー．ハー．エム．エス ゲゼルシャフト ミット ベシュレンクテル ハフツング 内皮性機能／機能不全に関連した疾患に罹患している患者の血管作動性ホルモンに基づいた層化
JP2013541015A (ja) 2010-11-01 2013-11-07 ベー．エル．アー．ハー．エム．エス ゲゼルシャフト ミット ベシュレンクテル ハフツング 非特異的症状を有する患者の予後及びリスク評価
US20130302841A1 (en) 2010-11-01 2013-11-14 B.R.A.H.M.S Gmbh Prognosis and risk assessment of patients with non-specific complaints
JP2016521315A (ja) 2013-04-19 2016-07-21 ユナイテッド テクノロジーズ コーポレイションＵｎｉｔｅｄ Ｔｅｃｈｎｏｌｏｇｉｅｓ Ｃｏｒｐｏｒａｔｉｏｎ 付加製造のためのビルドプレート及び装置

Non-Patent Citations (7)

* Cited by examiner, † Cited by third party
Title
Darius Cameron Wilson，Early sepsis identification following cytoreductive surgery for peritoneal malignancy，Critical Care，2020年，Vol.24，Page.112
Francesco Travaglino，Utility of Procalcitonin (PCT) and Mid regional pro-Adrenomedullin (MR-proADM) in risk stratification of critically ill febrile patients in Emergency Department (ED). A comparison with APACHE II score，BMC Infectious Diseases，2012年08月08日，Vol.12，Page.184
Jochen Gille，MR-proADM: A New Biomarker for Early Diagnosis of Sepsis in Burned Patients，Journal of Burn Care & Research，2017年09月01日，Vol.38 No.5，Pages 290-298
Munirah Al Shuaibi，Pro-adrenomedullin as a Novel Biomarker for Predicting Infections and Response to Antimicrobials in Febrile Patients With Hematologic Malignancies，Clinical Infectious Diseases，2013年01月03日，Vol.56 No.7，Page.943-950
MUNIRAH AL SHUAIBI; ET AL，PRO-ADRENOMEDULLIN AS A NOVEL BIOMARKER FOR PREDICTING INFECTIONS AND RESPONSE TO ANTIMICROBIALS IN FEBRILE PATIENTS WITH HEMATOLOGIC MALIGNANCIES，CLINICAL INFECTIOUS DISEASES，米国，THE UNIVERSITY OF CHICAGO PRESS，2013年01月03日，VOL:56, NR:7，PAGE(S):943 - 950，http://dx.doi.org/10.1093/cid/cis1029
Oliver Hartm，Time-dependent Cox regression: Serial measurement of the cardiovascular biomarker proadrenomedullin improves survival prediction in patients with lower respiratory tract infection，International Journal of Cardiology，2012年09月24日，Vol.161 No.3，Page.166-173
Pierre-Emmanuel Charles，MR-PROADM ELEVATION UPON ICU ADMISSION PREDICTS THE OUTCOME OF SEPTIC PATIENTS AND IS CORRELATED WITH UPCOMING FLUID OVERLOAD，SHOCK，2017年10月，Vol.48 No.4，Page.418-426

Also Published As

Publication number Publication date
BR112020004138A2 (pt) 2020-09-08
RU2020111719A3 (https=) 2021-12-17
JP2020533604A (ja) 2020-11-19
US20200300864A1 (en) 2020-09-24
US20250189539A1 (en) 2025-06-12
EP3682246A1 (en) 2020-07-22
CN111094986B (zh) 2023-11-10
WO2019053116A1 (en) 2019-03-21
JP7366007B2 (ja) 2023-10-20
CN111065927B (zh) 2023-10-17
US20200271667A1 (en) 2020-08-27
EP3682245A1 (en) 2020-07-22
CN111094986A (zh) 2020-05-01
WO2019053116A8 (en) 2022-03-17
JP2023181226A (ja) 2023-12-21
WO2019053115A1 (en) 2019-03-21
JP7544879B2 (ja) 2024-09-03
CN111065927A (zh) 2020-04-24
US12517138B2 (en) 2026-01-06
RU2020111719A (ru) 2021-10-13
JP2023041741A (ja) 2023-03-24
JP2020537117A (ja) 2020-12-17
CA3075440A1 (en) 2019-03-21

Similar Documents

Publication Publication Date Title
JP2025019061A (ja) 術後有害事象の診断または予後
JP7579353B2 (ja) 重症急性呼吸器症候群（ｓａｒｓ）における疾患進行を予後診断するためのプロアドレノメデュリン
US20250189539A1 (en) Sample including pro-adm as a therapy monitoring marker for critcally ill patients
JP2024023615A (ja) 感染性疾患の症状を有する患者において入院を必要とする病状のリスクを予測するためのｐｒｏ－ａｄｍ
JP2023095851A (ja) 抗生物質治療をモニタリングするためのマーカーとしてのｐｃｔおよびｐｒｏ－ａｄｍ
US12153057B2 (en) Antibiotic therapy guidance based on procalcitonin in patients with comorbidities
JP7346389B2 (ja) 異常な血小板レベルのマーカーとしてのプロアドレノメジュリン
RU2782305C2 (ru) Про-адм в качестве маркера мониторинга терапии для критически больных пациентов
RU2788885C2 (ru) Прокальцитонин и про-адм в качестве маркеров для мониторинга лечения антибиотиками
HK40077959A (en) Pro-adm for therapy monitoring of intensive care unit patients
HK40031519B (en) Pct and pro-adm as markers for monitoring antibiotic treatment

Legal Events

Date Code Title Description
A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20210208

A621 Written request for application examination

Free format text: JAPANESE INTERMEDIATE CODE: A621

Effective date: 20210208

A977 Report on retrieval

Free format text: JAPANESE INTERMEDIATE CODE: A971007

Effective date: 20211228

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20220131

A601 Written request for extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A601

Effective date: 20220427

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20220630

A02 Decision of refusal

Free format text: JAPANESE INTERMEDIATE CODE: A02

Effective date: 20220920

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20230119

C60 Trial request (containing other claim documents, opposition documents)

Free format text: JAPANESE INTERMEDIATE CODE: C60

Effective date: 20230119

C11 Written invitation by the commissioner to file amendments

Free format text: JAPANESE INTERMEDIATE CODE: C11

Effective date: 20230130

A911 Transfer to examiner for re-examination before appeal (zenchi)

Free format text: JAPANESE INTERMEDIATE CODE: A911

Effective date: 20230320

C21 Notice of transfer of a case for reconsideration by examiners before appeal proceedings

Free format text: JAPANESE INTERMEDIATE CODE: C21

Effective date: 20230323

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20230522

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20230524

TRDD Decision of grant or rejection written
A01 Written decision to grant a patent or to grant a registration (utility model)

Free format text: JAPANESE INTERMEDIATE CODE: A01

Effective date: 20230713

A61 First payment of annual fees (during grant procedure)

Free format text: JAPANESE INTERMEDIATE CODE: A61

Effective date: 20230807

R150 Certificate of patent or registration of utility model

Ref document number: 7329503

Country of ref document: JP

Free format text: JAPANESE INTERMEDIATE CODE: R150